Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naïve HIV-Infected Participants.
Schürmann D, Hüser A, Pfäfflin F, Cilissen C, De Lepeleire I, Larson PJ, Anderson MS, Rizk ML, Hofmann J, Däumer M, Stegemann MS, Stoch SA, Wagner F, Iwamoto M. Schürmann D, et al. Among authors: stoch sa. AIDS Res Hum Retroviruses. 2024 Oct 3. doi: 10.1089/AID.2023.0152. Online ahead of print. AIDS Res Hum Retroviruses. 2024. PMID: 39291814
Clinical Evaluation of MK-2640: An Insulin Analog With Glucose-Responsive Properties.
Krug AW, Visser SAG, Tsai K, Kandala B, Fancourt C, Thornton B, Morrow L, Kaarsholm NC, Bernstein HS, Stoch SA, Crutchlow M, Kelley DE, Iwamoto M. Krug AW, et al. Among authors: stoch sa. Clin Pharmacol Ther. 2019 Feb;105(2):417-425. doi: 10.1002/cpt.1215. Epub 2018 Sep 30. Clin Pharmacol Ther. 2019. PMID: 30125349 Clinical Trial.
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
Schürmann D, Rudd DJ, Zhang S, De Lepeleire I, Robberechts M, Friedman E, Keicher C, Hüser A, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Matthews RP. Schürmann D, et al. Among authors: stoch sa. Lancet HIV. 2020 Mar;7(3):e164-e172. doi: 10.1016/S2352-3018(19)30372-8. Epub 2020 Jan 3. Lancet HIV. 2020. PMID: 31911147 Clinical Trial.
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV.
Matthews RP, Ankrom W, Friedman E, Jackson Rudd D, Liu Y, Mogg R, Panebianco D, De Lepeleire I, Petkova M, Grobler JA, Stoch SA, Iwamoto M. Matthews RP, et al. Among authors: stoch sa. Clin Transl Sci. 2021 Sep;14(5):1935-1944. doi: 10.1111/cts.13048. Epub 2021 Aug 31. Clin Transl Sci. 2021. PMID: 34463432 Free PMC article. Clinical Trial.
Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate.
Rudd DJ, Zhang S, Fillgrove KL, Fox-Bosetti S, Matthews RP, Friedman E, Armas D, Stoch SA, Iwamoto M. Rudd DJ, et al. Among authors: stoch sa. Clin Pharmacol Drug Dev. 2021 Dec;10(12):1432-1441. doi: 10.1002/cpdd.1026. Epub 2021 Oct 22. Clin Pharmacol Drug Dev. 2021. PMID: 34676683 Free PMC article. Clinical Trial.
A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
Ankrom W, Jackson Rudd D, Zhang S, Fillgrove KL, Gravesande KN, Matthews RP, Brimhall D, Stoch SA, Iwamoto MN. Ankrom W, et al. Among authors: stoch sa. J Int AIDS Soc. 2021 Dec;24(12):e25858. doi: 10.1002/jia2.25858. J Int AIDS Soc. 2021. PMID: 34935295 Free PMC article. Clinical Trial.
113 results